Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulranumab Monotherapy for Pain in Knee Osteoarthritis
NCT01094262Phase 2Terminated
- Sponsor
- Johnson & Johnson
- Start
- Apr 2010
- Primary completion
- Jul 2011
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of fulranumab in osteoarthritis (OA), sponsored by Johnson & Johnson. Started Apr 2010; status: terminated.
02
Drugs
fulranumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT01094262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01094262.